Cardiac output

Cardiac Monitoring and Cardiac Rhythm Management Devices Market worth $26.8 billion by 2025 - Exclusive Report by MarketsandMarkets™

Wednesday, September 23, 2020 - 3:30pm

On the basis of cardiac monitoring devices by type, the market is segmented into ECG devices, event monitors, implantable loop recorders (ILRs), cardiac output monitoring (COM) devices, mobile cardiac telemetry (MCT) devices, and smart ECG monitors.

Key Points: 
  • On the basis of cardiac monitoring devices by type, the market is segmented into ECG devices, event monitors, implantable loop recorders (ILRs), cardiac output monitoring (COM) devices, mobile cardiac telemetry (MCT) devices, and smart ECG monitors.
  • In 2019, the ECG devices segment accounted for the largest share of the market.
  • On the basis of cardiac rhythm management devices by type, the market is segmented into defibrillators and pacemakers.
  • By end user, the cardiac rhythm management devices market is segmented into hospitals; clinics, cardiac centers, and ambulatory surgery centers (ASCs); and other end users.

Cardiac Monitoring and Cardiac Rhythm Management Devices Market worth $26.8 billion by 2025 - Exclusive Report by MarketsandMarkets™

Wednesday, September 23, 2020 - 3:30pm

On the basis of cardiac monitoring devices by type, the market is segmented into ECG devices, event monitors, implantable loop recorders (ILRs), cardiac output monitoring (COM) devices, mobile cardiac telemetry (MCT) devices, and smart ECG monitors.

Key Points: 
  • On the basis of cardiac monitoring devices by type, the market is segmented into ECG devices, event monitors, implantable loop recorders (ILRs), cardiac output monitoring (COM) devices, mobile cardiac telemetry (MCT) devices, and smart ECG monitors.
  • In 2019, the ECG devices segment accounted for the largest share of the market.
  • On the basis of cardiac rhythm management devices by type, the market is segmented into defibrillators and pacemakers.
  • By end user, the cardiac rhythm management devices market is segmented into hospitals; clinics, cardiac centers, and ambulatory surgery centers (ASCs); and other end users.

DGAP-News: 4TEEN4's first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis

Wednesday, September 16, 2020 - 9:01am

The study data (1) from the team lead by Prof. Alexandre Mebazaa have shown that high DPP3 blood values are associated with decreased heart function in a preclinical sepsis model.

Key Points: 
  • The study data (1) from the team lead by Prof. Alexandre Mebazaa have shown that high DPP3 blood values are associated with decreased heart function in a preclinical sepsis model.
  • In this randomized, controlled study, the administration of Procizumab immediately and significantly improved heart function by increasing cardiac output, stroke volume, and left ventricular shortening fraction.
  • By inhibiting DPP3 with our antibody Procizumab, we are able to restore cardiac function in preclinical sepsis models.
  • This inactivation leads to cardiac depression and consequently hemodynamic instability and consequently cardiac depression.

RSNA: 3D Ultrasound Enables Accurate, Noninvasive Measurements of Blood Flow

Tuesday, June 30, 2020 - 3:00pm

In emergency situations, accurate blood flow measurements can show if there is adequate blood supply to organs like the heart and brain.

Key Points: 
  • In emergency situations, accurate blood flow measurements can show if there is adequate blood supply to organs like the heart and brain.
  • Blood flow measurements are important in chronic conditions too, as in the cases of measuring blood flow to the feet and lower limbs of people with diabetes.
  • True flow measurements with 2D ultrasound are rarely used clinically due to reliability issues and cumbersome implementation.
  • The results showed that blood volume flow estimated by 3D color-flow ultrasound was accurate and reproducible among the seven laboratories.

RSNA: MRI Shows Blood Flow Differs in Men and Women, According to New Research

Thursday, February 27, 2020 - 4:00pm

However, much less is known about the way that blood flows through the hearts of men and women and how that relates to cardiac performance.

Key Points: 
  • However, much less is known about the way that blood flows through the hearts of men and women and how that relates to cardiac performance.
  • They derived various blood flow parameters from MRI scans obtained from 20 men and 19 women and correlated them with cardiac function.
  • Dr. Rutkowski emphasized that the ability of 4D flow MRI to provide numbers for various blood flow parameters is especially important.
  • "Getting blood flow and velocity information is just one more metric that is being developed to make MRI more quantitative."

Global Cardiac Output Monitoring Devices Market Drivers, Restraints, Trends & Opportunities, 2019-2027 - ResearchAndMarkets.com

Monday, February 3, 2020 - 5:18pm

The report also provides the compound annual growth rate (CAGR) for the global cardiac output monitoring devices market for the forecast period.

Key Points: 
  • The report also provides the compound annual growth rate (CAGR) for the global cardiac output monitoring devices market for the forecast period.
  • Furthermore, the report sheds light on the changing competitive dynamics in the global cardiac output monitoring devices market.
  • The next section of the global cardiac output monitoring devices report highlights the USPs, which include key industry developments in the global cardiac monitoring devices market, regulatory scenario, and technological advancement in cardiac output monitoring devices.
  • It is followed by market introduction, market dynamics, and an overview of the global cardiac output monitoring devices market, which includes an analysis of market drivers, restraints, and trends affecting the growth of the global cardiac monitoring devices market.

Cardiac Output Monitoring Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Thursday, January 30, 2020 - 2:05pm

Analysts have also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global cardiac monitoring devices market.

Key Points: 
  • Analysts have also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global cardiac monitoring devices market.
  • The next section of the global cardiac output monitoring devices report highlights the USPs, which include key industry developments in the global cardiac monitoring devices market, regulatory scenario, and technological advancement in cardiac output monitoring devices.
  • The report delves into the competitive landscape of the global cardiac output monitoring devices market.Key players operating in the global cardiac monitoring devices market have been identified, and each one of them has been profiled for their distinguishing business attributes.
  • It is followed by market introduction, market dynamics, and an overview of the global cardiac output monitoring devices market, which includes analysis of market drivers, restraints, and trends affecting the growth of the global cardiac monitoring devices market.Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends in the cardiac monitoring devices market.

RETIA MEDICAL Announces Two Publications of Independent Validation Studies of its Argos Cardiac Output Monitor in off-pump coronary artery bypass surgical (OR) patients and high-risk post-cardiac surgical patients in the ICU

Wednesday, September 4, 2019 - 1:00pm

VALHALLA, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Retia Medical, LLC announced today the recent publications of two independent validation studies which confirmed the accuracy of the minimally invasive Argos Hemodynamic Monitor for monitoring cardiac output in off-pump cardiac bypass graft (OPCAB) patients during their OR procedures and recovery in the CTICU.

Key Points: 
  • VALHALLA, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Retia Medical, LLC announced today the recent publications of two independent validation studies which confirmed the accuracy of the minimally invasive Argos Hemodynamic Monitor for monitoring cardiac output in off-pump cardiac bypass graft (OPCAB) patients during their OR procedures and recovery in the CTICU.
  • In two studies led by Bernd Saugel, MD from the University Medical Center Hamburg-Eppendorf in Hamburg, Germany, clinicians compared 572 paired (before/after intervention) CO measurements of a total of 58 OPCAB surgical patients and 167 paired (before/after intervention) CO measurements of 31 Intensive Care Unit patients.
  • We are grateful to have had the opportunity to provide the Argos monitor to Dr. Saugel and his team, who led an especially rigorous test of the performance of our monitor.
  • Retia Medical designed the Argos Cardiac Output (CO) Monitor to provide members of the Critical Care team in the operating room and intensive care unit with a more accurate, intuitive and affordable hemodynamic monitor that supports confident, data-based patient care decision making.

Telehealth Technology to Reduce Hospital Readmissions and Improve Outcomes for Cardiac Disease Patients

Tuesday, July 16, 2019 - 12:00pm

This technology provides a way for remote specialists to treat cardiac patients in place and identify high risk patients before they are symptomatic.

Key Points: 
  • This technology provides a way for remote specialists to treat cardiac patients in place and identify high risk patients before they are symptomatic.
  • The MyNICaS hemodynamic profiling used in telehealth applications allows remote physicians to get an accurate reading of patients cardiac output and fluid status to determine treatment right away and improve their clinical outcomes.
  • The reading of stroke volume, cardiac output, cardiac power index, total peripheral resistance and total body water provide remote specialists with the data they need to treat patients in place and avoid exacerbations or hospital readmissions.
  • AMD Global Telemedicine (AMD) creates telehealth solutions that empower healthcare organizations to deliver care through digital technology.

New Studies Suggest That DiA's AI-based Software, LVivo EF, Is Accurate and Efficient in Assessing Ejection Fraction Values Compared to Cardiac MRI and Contrast Echocardiography

Wednesday, June 19, 2019 - 2:00pm

LVivo EF aims to substantially reduce this variability by generating objective, accurate and fast AI-based EF.

Key Points: 
  • LVivo EF aims to substantially reduce this variability by generating objective, accurate and fast AI-based EF.
  • The first study: " Validation of a Novel Artificial Intelligence Left Ventricular Ejection Fraction Quantification Software (LVivo EF by DIA) by Cardiac MRI" tested the accuracy of the LVivo EF tool on 76 patients by retrospectively running it on cardiac 4 chamber clips .
  • The LVivo EF results were then compared to those obtained by MRI EF as a gold standard.
  • "This study further validated DiA's AI-based tool, LVivo EF, against cardiac MRI EF, a recognized gold standard for the assessment of cardiac function.